{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:44:02Z","timestamp":1792633442498,"version":"4.5.0"},"reference-count":260,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is a neurodegenerative disorder that features progressive, disabling motor symptoms, such as bradykinesia, rigidity, and resting tremor. Nevertheless, some non-motor symptoms, including depression, REM sleep behavior disorder, and olfactive impairment, are even earlier features of PD. At later stages, apathy, impulse control disorder, neuropsychiatric disturbances, and cognitive impairment can present, and they often become a heavy burden for both patients and caregivers. Indeed, PD increasingly compromises activities of daily life, even though a high variability in clinical presentation can be observed among people affected. Nowadays, symptomatic drugs and non-pharmaceutical treatments represent the best therapeutic options to improve quality of life in PD patients. The aim of the present review is to provide a practical, stage-based guide to pharmacological management of both motor and non-motor symptoms of PD. Furthermore, warning about drug side effects, contraindications, as well as dosage and methods of administration, are highlighted here, to help the physician in yielding the best therapeutic strategies for each symptom and condition in patients with PD.<\/jats:p>","DOI":"10.3390\/biom9080388","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T11:19:06Z","timestamp":1566386346000},"page":"388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["A Stage-Based Approach to Therapy in Parkinson\u2019s Disease"],"prefix":"10.3390","volume":"9","author":[{"given":"Claudia","family":"Carrarini","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-5923","authenticated-orcid":false,"given":"Mirella","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3575-2942","authenticated-orcid":false,"given":"Fedele","family":"Dono","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Di Pietro","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna G.","family":"Rispoli","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9805-1655","authenticated-orcid":false,"given":"Vincenzo","family":"Di Stefano","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ferri","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Barbone","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Vitale","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0710-2574","authenticated-orcid":false,"given":"Stefano Luca","family":"Sensi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Onofrj","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonanni","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson\u2019s disease: Clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: A review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jnnp.2006.100370","article-title":"Insomnia in Parkinson\u2019s disease: Frequency and progression over time","volume":"78","author":"Gjerstad","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/pmj.77.904.89","article-title":"Parkinson\u2019s disease and anxiety","volume":"77","author":"Walsh","year":"2001","journal-title":"Postgrad. Med. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00702-004-0168-1","article-title":"Cognitive dysfunction and dementia in Parkinson\u2019s disease","volume":"111","author":"Bosboom","year":"2004","journal-title":"J. Neural Transm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp.73.6.636","article-title":"Apathy in Parkinson\u2019s disease","volume":"73","author":"Pluck","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.26121","article-title":"Behavioral effects of levodopa","volume":"30","author":"Lang","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00702-007-0855-9","article-title":"Bladder and bowel dysfunction in Parkinson\u2019s disease","volume":"115","author":"Sakakibara","year":"2008","journal-title":"J. Neural Transm."},{"key":"ref_10","first-page":"685","article-title":"The Effects of Physical Activity in Parkinson\u2019s Disease: A Review","volume":"6","author":"Daneault","year":"2016","journal-title":"J. Park. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: Onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jnc.13691","article-title":"The clinical symptoms of Parkinson\u2019s disease","volume":"139","author":"Sveinbjornsdottir","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/mds.25898","article-title":"Mortality in Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"29","author":"Macleod","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"MDS research criteria for prodromal Parkinson\u2019s disease","volume":"30","author":"Berg","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00401-007-0193-x","article-title":"Parkinson\u2019s disease: Lesions in dorsal horn layer I, involvement of para-sympathetic and sympathetic pre-and postganglionic neurons","volume":"113","author":"Braak","year":"2007","journal-title":"Acta Neuropathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mds.24996","article-title":"Identifying prodromal Parkinson\u2019s disease: Pre-motor disorders in Parkinson\u2019s disease","volume":"27","author":"Postuma","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","article-title":"3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists","volume":"180","author":"Carlsson","year":"1957","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pneurobio.2016.07.002","article-title":"Expanding the repertoire of l-DOPA\u2019s actions: A comprehensive review of its functional neurochemistry","volume":"151","author":"Millan","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Foley, P. (2000). The l-DOPA story revisited. Further surprises to be expected?. J. Neural Transm. Suppl., 1\u201320.","DOI":"10.1007\/978-3-7091-6301-6_1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.62.5.436","article-title":"Olfactory dysfunction in Parkinson\u2019s disease","volume":"62","author":"Hawkes","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1212\/WNL.0000000000000960","article-title":"Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study","volume":"83","author":"Jennings","year":"2014","journal-title":"Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1212\/WNL.0000000000001265","article-title":"Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD","volume":"84","author":"Mahlknecht","year":"2015","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/brain\/awf251","article-title":"Clinical correlates of selective pathology in the amygdala of patients with Parkinson\u2019s disease","volume":"125","author":"Harding","year":"2002","journal-title":"Brain"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/jnnp.55.2.138","article-title":"Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson\u2019s disease","volume":"55","author":"Doty","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/ane.13003","article-title":"Hyposmia in a simple smell test is associated with accelerated cognitive decline in early Parkinson\u2019s disease","volume":"138","author":"Gjerde","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrneurol.2012.80","article-title":"Olfactory dysfunction in Parkinson disease","volume":"8","author":"Doty","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jns.2018.08.008","article-title":"Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: A scoping review","volume":"393","author":"Pachito","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/mds.26350","article-title":"Probable RBD and association with neurodegenerative disease markers: A population-based study","volume":"30","author":"Mahlknecht","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1474-4422(06)70476-8","article-title":"Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: A descriptive study","volume":"5","author":"Iranzo","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/mds.22099","article-title":"Manifestations of Parkinson disease differ in association with REM sleep behavior disorder","volume":"23","author":"Postuma","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0002-9343(97)89493-4","article-title":"Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults","volume":"100","author":"Schenck","year":"1996","journal-title":"Am. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/brain\/123.2.331","article-title":"Rapid eye movement sleep behavior disorder: Demographic, clinical, and laboratory findings in 93 cases","volume":"123","author":"Olson","year":"2000","journal-title":"Brain"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2869.1993.tb00093.x","article-title":"Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: An update on a series of 96 patients and a review of the world literature","volume":"2","author":"Schenck","year":"1993","journal-title":"J. Sleep Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5664\/jcsm.27717","article-title":"Best practice guide for the treatment of REM sleep behavior disorder (RBD)","volume":"6","author":"Aurora","year":"2010","journal-title":"J. Clin. Sleep Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1056\/NEJM199701163360306","article-title":"Melatonin in humans","volume":"336","author":"Brzezinski","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.sleep.2012.09.018","article-title":"Treatment outcomes in REM sleep behavior disorder","volume":"14","author":"Mcarter","year":"2013","journal-title":"Sleep Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1440-1819.2001.00854.x","article-title":"Melatonin therapy for REM sleep behavior disorder","volume":"55","author":"Takeuchi","year":"2001","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1389-9457(03)00072-8","article-title":"Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: Results in 14 patients","volume":"4","author":"Boeve","year":"2003","journal-title":"Sleep Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2869.2010.00848.x","article-title":"A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder","volume":"19","author":"Kunz","year":"2010","journal-title":"J. Sleep Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/JCP.0b013e31826866f8","article-title":"Agomelatine may improve REM sleep behavior disorder symptoms","volume":"32","author":"Bonakis","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2169\/internalmedicine.55.5464","article-title":"Beneficial Effects of Ramelteon on Rapid Eye Movement Sleep Behavior Disorder Associated with Parkinson\u2019s Disease\u2014Results of a Multicenter Open Trial","volume":"55","author":"Kashihara","year":"2016","journal-title":"Intern. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/mds.10233","article-title":"Decreased phasic EMG activity during rapid eye movement sleep in treatment-naive Parkinson\u2019s disease: Effects of treatment with levodopa and progression of illness","volume":"17","author":"Caminero","year":"2002","journal-title":"Mov. Disord."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clineuro.2004.09.021","article-title":"Clinical features of 35 patients with Parkinson\u2019s disease displaying REM behavior disorder","volume":"107","author":"Ozekmekci","year":"2005","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/WNL.61.10.1418","article-title":"The effects of pramipexole in REM sleep behavior disorder","volume":"61","author":"Fantini","year":"2003","journal-title":"Neurology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.parkreldis.2012.08.010","article-title":"Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder","volume":"19","author":"Sasai","year":"2013","journal-title":"Park. Relat. Disord."},{"key":"ref_47","first-page":"1418","article-title":"Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease","volume":"31","author":"Kumru","year":"2008","journal-title":"Sleep"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/sleep\/20.9.757","article-title":"Contributions of the pedunculopontine region to normal and altered REM sleep","volume":"20","author":"Rye","year":"1997","journal-title":"Sleep"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0006-8993(82)90835-6","article-title":"Different behaviors during paradoxical sleep without atonia depend on pontine lesion site","volume":"239","author":"Hendricks","year":"1982","journal-title":"Brain Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0006-8993(89)91549-7","article-title":"Cholinergic activation of medial pontine reticular formation neurons in vitro","volume":"476","author":"Greene","year":"1989","journal-title":"Brain Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/brain\/awm056","article-title":"Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease","volume":"130","author":"Boeve","year":"2007","journal-title":"Brain."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/gps.2506","article-title":"The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson\u2019s disease dementia","volume":"25","author":"Larsson","year":"2010","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/WNF.0b013e318193e394","article-title":"Successful treatment of REM sleep behavior disorder with sodium oxybate","volume":"32","author":"Shneerson","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.sleep.2016.04.014","article-title":"Sodium oxybate for idiopathic REM sleep behavior disorder: A report on two patients","volume":"32","author":"Moghadam","year":"2017","journal-title":"Sleep Med."},{"key":"ref_55","first-page":"564","article-title":"Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: A case series","volume":"39","author":"Chagas","year":"2014","journal-title":"J. Clin. Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/mds.870060211","article-title":"Gastrointestinal symptoms in Parkinson\u2019s disease","volume":"6","author":"Edwards","year":"1991","journal-title":"Mov. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1212\/WNL.0b013e3181c34af5","article-title":"Medical records documentation of constipation preceding Parkinson disease: A case-control study","volume":"73","author":"Savica","year":"2009","journal-title":"Neurology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41531-018-0042-8","article-title":"Management of constipation in patients with Parkinson\u2019s disease","volume":"4","author":"Timmermann","year":"2018","journal-title":"NPJ Park. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/ane.12010","article-title":"Autonomic symptoms and dopaminergic treatment in de novo Parkinson\u2019s disease","volume":"127","author":"Muller","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.parkreldis.2014.11.015","article-title":"Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson\u2019s disease","volume":"21","author":"Pagano","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.parkreldis.2011.06.002","article-title":"Levodopa ameliorated anorectal constipation in de novo Parkinson\u2019s disease: The Ql-GAT study","volume":"17","author":"Tateno","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1468-1331.2009.02900.x","article-title":"Neurotransmission in Parkinson\u2019s disease: Beyond dopamine","volume":"17","author":"Barone","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/WNL.36.8.1130","article-title":"Parkinson\u2019s disease with depression: A possible subgroup of idiopathic parkinsonism","volume":"36","author":"Santamaria","year":"1986","journal-title":"Neurology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00536.x","article-title":"Depression in Parkinson\u2019s Disease\u2014Review","volume":"113","author":"Lieberman","year":"2006","journal-title":"Acta Neurol. Scand."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1176\/jnp.4.3.257","article-title":"Preliminary examination of the comorbidity of anxiety and depression in Parkinson\u2019s disease","volume":"4","author":"Henderson","year":"1992","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","article-title":"The Movement Disorder Society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson\u2019s disease","volume":"26","author":"Seppi","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00415-007-5008-4","article-title":"Depression in Parkinson\u2019s Disease","volume":"254","author":"Poewe","year":"2007","journal-title":"J. Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1586\/14737175.2015.1038244","article-title":"Parkinson\u2019s disease: A review of non-motor symptoms","volume":"15","author":"Rana","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jnnp-2018-319375","article-title":"Impulse control disorders in Parkinson\u2019s disease: A hard-turning point","volume":"90","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fneur.2018.00330","article-title":"Impulse-Control Disorders in Parkinson\u2019s Disease: A Meta-Analysis and Review of Case\u2013Control Studies","volume":"9","author":"Molde","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/jnnp-2012-302684","article-title":"Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic","volume":"84","author":"Pondal","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1756285609339383","article-title":"Improving Symptom Control in Early Parkinson\u2019s Disease","volume":"2","author":"Isaacson","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/096368979700600313","article-title":"Comparison of neurotoxicity following repeated administration of l-dopa, D-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors","volume":"6","author":"Alexander","year":"1997","journal-title":"Cell Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archneur.56.5.529","article-title":"Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later l-DOPA","volume":"56","author":"Fahn","year":"1999","journal-title":"Arch. Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0168-5597(88)90050-0","article-title":"Alterations in event-related potentials (ERPs) of MPTP-treated monkeys","volume":"71","author":"Glover","year":"1988","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0024-3205(88)90315-3","article-title":"Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates","volume":"43","author":"Ghilardi","year":"1988","journal-title":"Life Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1600-0404.1976.tb04355.x","article-title":"Parkinson\u2019s disease treated with Sinemet or Madopar. A controlled multicenter trial","volume":"53","author":"Pakkenberg","year":"1976","journal-title":"Acta Neurol. Scand."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2174\/1570159X13666151030102718","article-title":"Anti-Oxidants in Parkinson\u2019s Disease Therapy: A Critical Point of View","volume":"14","author":"Filograna","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Park, H.J., Kang, J.K., and Lee, M.K. (2019). 1-O-Hexyl-2,3,5-Trimethylhydroquinone Ameliorates l-DOPA-Induced Cytotoxicity in PC12 Cells. Molecules, 24.","DOI":"10.3390\/molecules24050867"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2016.12.070","article-title":"Dopamine agonist withdrawal syndrome: A comprehensive review","volume":"374","author":"Yu","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1172\/JCI117946","article-title":"Induction of apoptosis in catecholaminergic PC12 cells by l-DOPA. Implications for the treatment of Parkinson\u2019s disease","volume":"95","author":"Walkinshaw","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_84","first-page":"37","article-title":"Side effects of a dopamine agonist therapy for Parkinson\u2019s disease: A mini-review of clinical pharmacology","volume":"89","author":"Borovac","year":"2016","journal-title":"Yale J. Biol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Stowe, R.L., Ives, N.J., Clarke, C., van Hilten, J., Ferreira, J., Hawker, R.J., Shah, L., Wheatley, K., and Gray, R. (2008). Dopamine agonist therapy in early Parkinson\u2019s disease. Cochrane Database Syst. Rev., CD006564.","DOI":"10.1002\/14651858.CD006564.pub2"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00002826-199508000-00006","article-title":"Pramipexole in patients with early Parkinson\u2019s disease","volume":"18","author":"Hubble","year":"1995","journal-title":"Clin. Neuropharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mds.870090409","article-title":"Pergolide compared with bromocriptine in Parkinson\u2019s disease: A multicenter, crossover, controlled study","volume":"9","author":"Pezzoli","year":"1994","journal-title":"Mov. Disord."},{"key":"ref_88","unstructured":"(2019). Mirapex (pramipexole dihydrochloride) [product monograph], Boehringer Ingelheim (Canada) Ltd.. Available online: https:\/\/www.boehringer-ingelheim.ca\/sites\/ca\/files\/documents\/mirapexpmen.pdf."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jns.2011.06.043","article-title":"Neural reward processing under dopamine agonists: Imaging","volume":"310","author":"Kassubek","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"ref_90","first-page":"541","article-title":"Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans","volume":"51","author":"Schilling","year":"1992","journal-title":"Clin. Pharm."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.0000000000001737","article-title":"Development of excessive daytime sleepiness in early Parkinson disease","volume":"85","author":"Tholfsen","year":"2015","journal-title":"Neurology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson disease","volume":"67","author":"Rabinak","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_93","first-page":"308","article-title":"Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson\u2019s disease center","volume":"379","author":"Patel","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (1989). DATATOP: A multicenter controlled clinical trial in early Parkinson\u2019s disease. Arch. Neurol., 46, 1052\u20131060.","DOI":"10.1001\/archneur.1989.00520460028009"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Crosby, N., Deane, K.H., and Clarke, C.E. (2003). Amantadine in Parkinson\u2019s disease. Cochrane Database Syst. Rev., CD003468.","DOI":"10.1002\/14651858.CD003468"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"104462","DOI":"10.1016\/j.nbd.2019.05.001","article-title":"Dystonia and Parkinson\u2019s disease: What is the relationship?","volume":"132","author":"Shetty","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Niemann, N., and Jankovic, J. (2019). Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Park. Relat. Disord.","DOI":"10.1016\/j.parkreldis.2019.06.025"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bmb\/ldn013","article-title":"A Review of Parkinson\u2019s disease","volume":"86","author":"Davie","year":"2008","journal-title":"Br. Med. Bull."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/14740338.4.1.69","article-title":"Tolcapone in Parkinson\u2019s disease: Liver toxicity and clinical efficacy","volume":"4","author":"Borges","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/archneur.57.2.263","article-title":"Tolcapone and Hepatotoxic effects","volume":"57","author":"Warre","year":"2000","journal-title":"Arch. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.53.5.1012","article-title":"Immediate-release and controlled-release carbidopa\/levodopa in PD: A 5-year randomized multicenter study. Carbidopa\/Levodopa Study Group","volume":"53","author":"Koller","year":"1999","journal-title":"Neurology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1468-1331.2009.02726.x","article-title":"Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson_s disease: A long-term, retrospective analysis","volume":"16","author":"Nissinen","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","article-title":"Opicapone as adjunct to levodopa therapy in patients with Parkinson\u2019s disease and motor fluctuation: A randomized clinical trial","volume":"74","author":"Less","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (1996). Effect of lazabemide on the progression of disability in early Parkinson\u2019s disease. Ann. Neurol., 40, 99\u2013107.","DOI":"10.1002\/ana.410400116"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/bmj.38184.606169.AE","article-title":"Monoamine oxidase type B inhibitors in early Parkinson\u2019s disease: Meta-analysis of 17 randomised trials involving 3525 patients","volume":"329","author":"Ives","year":"2004","journal-title":"BMJ"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1212\/01.WNL.0000134672.44217.F7","article-title":"Improvement of motor function in early Parkinson\u2019s disease by safinamide","volume":"63","author":"Stocchi","year":"2004","journal-title":"Neurology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e3181f6128c","article-title":"Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease","volume":"75","author":"Chung","year":"2010","journal-title":"Neurology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","article-title":"Rivastigmine for gait stability in patients with Parkinson\u2019s disease (ReSPonD): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Henderson","year":"2016","journal-title":"Lancet"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1474-4422(06)70574-9","article-title":"Treatment of dystonia","volume":"5","author":"Jankovic","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","article-title":"EFNS guidelines on diagnosis and treatment of primary dystonias","volume":"18","author":"Albanese","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/mds.23823","article-title":"MDS task force on mild cognitive impairment in Parkinson\u2019s disease: Critical review of PD-MCI","volume":"26","author":"Litvan","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1212\/01.WNL.0000036610.36834.E0","article-title":"The association of incident dementia with mortality in, P.D","volume":"59","author":"Levy","year":"2002","journal-title":"Neurology"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Rolinski, M., Fox, C., Maidment, I., and McShane, R. (2012). Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson\u2019s disease. Cochrane Database Syst. Rev., CD006504.","DOI":"10.1002\/14651858.CD006504.pub2"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/mds.26236","article-title":"Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study","volume":"30","author":"Mamikonyan","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp-2014-308764","article-title":"Cholinesterase inhibitors for Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"86","author":"Pagano","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.parkreldis.2010.12.003","article-title":"Memantine for non-motor features of Parkinson\u2019s disease: A double-blind placebo controlled exploratory pilot trial","volume":"17","author":"Ondo","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","article-title":"Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: A randomised, double-blind, placebo-controlled trial","volume":"9","author":"Emre","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/mds.26617","article-title":"Rasagiline for mild cognitive impairment in Parkinson\u2019s disease: A placebo-controlled trial","volume":"31","author":"Weintraub","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/mds.23738","article-title":"The effects of rasagiline on cognitive deficits in Parkinson\u2019s disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study","volume":"26","author":"Hanagasi","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1176\/appi.neuropsych.15050118","article-title":"Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson\u2019s Disease Without Dementia","volume":"29","author":"Frakey","year":"2017","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/bs.irn.2017.05.025","article-title":"Apathy in Parkinson\u2019s Disease","volume":"133","author":"Pagonabarraga","year":"2017","journal-title":"Nonmotor Park. Hidden Face Many Hidden Faces"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2013-306439","article-title":"Rivastigmine in apathetic but dementia and depression-free patients with Parkinson\u2019s disease: A double-blind, placebo-controlled, randomised clinical trial","volume":"85","author":"Devos","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson\u2019s disease: Report of an NINDS, NIMH work group","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11920-016-0730-1","article-title":"Current understanding of psychosis in Parkinson\u2019s disease","volume":"18","author":"Ojo","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/NDT.S116116","article-title":"Psychosis in parkinsonism: An unorthodox approach","volume":"13","author":"Onofrj","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1471-4159.1990.tb03162.x","article-title":"Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia","volume":"55","author":"Perry","year":"1990","journal-title":"J. Neurochem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"15222","DOI":"10.1073\/pnas.96.26.15222","article-title":"Thalamocortical dysrhythmia: A neurological and neuropsychiatric syndrome characterized by magnetoencephalography","volume":"96","author":"Llinas","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.22063","article-title":"Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson\u2019s disease with motor fluctuations","volume":"23","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2015.11.013","article-title":"Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson\u2019s disease patients","volume":"23","author":"Borgemeester","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4088\/JCP.v66n0514","article-title":"Neuroleptic sensitivity in Parkinson\u2019s disease and parkinsonian dementias","volume":"66","author":"Aarsland","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.amjopharm.2010.08.004","article-title":"Management of hallucinations and psychosis in Parkinson\u2019s disease","volume":"8","author":"Eng","year":"2010","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(01)00212-2","article-title":"Newer atypical antipsychotic medication in comparison to clozapine: A systematic review of randomized trials","volume":"56","author":"Tuunainen","year":"2002","journal-title":"Schizophr. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: Number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson\u2019s Disease Psychosis","volume":"35","author":"Meltzer","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: A randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/NDT.S108948","article-title":"Update on the treatment of Parkinson\u2019s disease psychosis: Role of pimavanserin","volume":"13","author":"Combs","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","article-title":"Psychosis in advanced Parkinson\u2019s disease: Treatment with ondansetron, a 5-HT3 receptor antagonist","volume":"45","author":"Zoldan","year":"1995","journal-title":"Neurology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40478-016-0334-3","article-title":"Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations","volume":"4","author":"Khundakar","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/gps.995","article-title":"What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson\u2019s disease with dementia","volume":"18","author":"Minett","year":"2003","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/0140-6736(91)91888-2","article-title":"Pharmacotoxic psychosis after memantine in Parkinson\u2019s disease","volume":"338","author":"Riederer","year":"1991","journal-title":"Lancet"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00455-015-9671-9","article-title":"Dysphagia in Parkinson\u2019s Disease","volume":"31","author":"Suttrup","year":"2015","journal-title":"Dysphagia"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00455-007-9100-9","article-title":"A pilot study of respiration and swallowing integration in Parkinson\u2019s disease: \u201con\u201d and \u201coff\u201d levodopa","volume":"23","author":"Lim","year":"2008","journal-title":"Dysphagia"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00455-015-9622-5","article-title":"Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson\u2019s Disease","volume":"30","author":"Hirano","year":"2015","journal-title":"Dysphagia"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10286-017-0434-6","article-title":"Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease","volume":"27","author":"Kremens","year":"2017","journal-title":"Clin. Auton. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/practneurol-2014-001000","article-title":"Management of orthostatic hypotension in patients with Parkinson\u2019s disease","volume":"15","author":"Wu","year":"2014","journal-title":"Pract. Neurol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/mdc3.12695","article-title":"Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease","volume":"5","author":"Hauser","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/HYPERTENSIONAHA.114.04035","article-title":"Randomized Withdrawal Study of Patients with Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa\u2014Novelty and Significance","volume":"65","author":"Biaggioni","year":"2014","journal-title":"Hypertension"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11255-011-9969-y","article-title":"Urinary tract dysfunction in Parkinson\u2019s disease: A review","volume":"44","author":"Yeo","year":"2011","journal-title":"Int. Urol. Nephrol."},{"key":"ref_154","first-page":"CD005429","article-title":"Which anticholinergic drug for overactive bladder symptoms in adults","volume":"1","author":"Madhuvrata","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mds.20867","article-title":"Bladder dysfunction in Parkinsonism: Mechanisms, prevalence, symptoms, and management","volume":"21","author":"Winge","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/17512433.2017.1275570","article-title":"Mirabegron for the treatment of overactive bladder: A review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia","volume":"10","author":"Chapple","year":"2017","journal-title":"J. Expert Rev. Clin. Pharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-018-0924-4","article-title":"Mirabegron: A Review in Overactive Bladder Syndrome","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bju.12730","article-title":"Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a \u03b23-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB)","volume":"115","author":"Rossanese","year":"2015","journal-title":"BJU Int."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/mds.27344","article-title":"Treatment of Autonomic Dysfunction in Parkinson Disease and Other Synucleinopathies","volume":"33","author":"Palma","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.62.6_suppl_4.S3","article-title":"Management of motor complications in Parkinson\u2019s disease","volume":"62","author":"Dewey","year":"2004","journal-title":"Neurology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-0037-1602423","article-title":"Motor Complications of Dopaminergic Medications in Parkinson\u2019s Disease","volume":"37","author":"Freitas","year":"2017","journal-title":"Semin. Neurol."},{"key":"ref_162","first-page":"1064","article-title":"Treating the Motor Symptoms of Parkinson Disease","volume":"22","author":"Morgan","year":"2016","journal-title":"Continuum"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40265-019-01098-w","article-title":"Contemporary Options for the Management of Motor Complications in Parkinson\u2019s Disease: Updated Clinical Review","volume":"79","author":"Cabreira","year":"2019","journal-title":"Drugs"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2165\/00023210-200822060-00005","article-title":"Intermittent subcutaneous apomorphine therapy for \u2018off\u2019 episodes in Parkinson\u2019s disease: A 6-month open-label study","volume":"22","author":"Trosch","year":"2008","journal-title":"CNS Drugs"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.26444\/aaem\/99699","article-title":"Continuous subcutaneous apomorphine monotherapy in Parkinson\u2019s disease","volume":"26","author":"Trzciniecka","year":"2019","journal-title":"Ann. Agric. Environ. Med."},{"key":"ref_166","first-page":"E98","article-title":"Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson\u2019s disease patients with motor fluctuations not well controlled on optimized medical treatment","volume":"89","author":"Katzenschlager","year":"2017","journal-title":"Neurology"},{"key":"ref_167","first-page":"197","article-title":"Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson\u2019s disease compared to conventional therapy: A real life study of non motor effect","volume":"1","author":"Reddy","year":"2011","journal-title":"J. Park. Dis."},{"key":"ref_168","first-page":"787","article-title":"Evaluating the efficacy of nocturnal continuous subcutaneous apomorphine infusion in sleep disorders in advanced parkinson\u2019s disease: The APO-NIGHT study","volume":"6","author":"Sesar","year":"2016","journal-title":"J. Park. Dis."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ana.410260209","article-title":"Peripheral pharmacokinetics of apomorphine in humans","volume":"26","author":"Gancher","year":"1989","journal-title":"Ann. Neurol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.clinthera.2005.11.016","article-title":"A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson\u2019s disease","volume":"27","author":"Chen","year":"2005","journal-title":"Clin. Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/mds.870080208","article-title":"Subcutaneous apomorphine in Parkinson\u2019s disease: Response to chronic administration for up to five years","volume":"8","author":"Hughes","year":"1993","journal-title":"Mov. Disord."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14656566.2017.1294683","article-title":"Opicapone for the treatment of Parkinson\u2019s disease","volume":"18","author":"Rodrigues","year":"2017","journal-title":"Expert Opin. Pharm."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Ferreira, J.J., Lees, A., Rocha, J.F., Poewe, W., Rascol, O., and Soares-da-Silva, P. (2019). Long-term efficacy of opicapone in fluctuating Parkinson\u2019s disease patients: A pooled-analysis of data from two Phase 3 clinical trials and their open-label extensions. Eur. J. Neurol., 26.","DOI":"10.1111\/ene.13914"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.62.1_suppl_1.S17","article-title":"The origin of motor fluctuations in Parkinson\u2019s disease: Importance of dopaminergic innervation and basal ganglia circuits","volume":"62","author":"Obeso","year":"2004","journal-title":"Neurology"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mds.26082","article-title":"Levodopa therapy for Parkinson\u2019s disease: Pharmacokinetics and pharmacodynamics","volume":"30","author":"LeWitt","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S1353-8020(09)70844-2","article-title":"Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson\u2019s disease","volume":"15","author":"Antonini","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40263-016-0386-8","article-title":"Novel Levodopa Formulations for Parkinson\u2019s Disease","volume":"30","author":"Freitas","year":"2016","journal-title":"CNS Drugs"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Hauser, R.A., Isaacson, S.H., Ellenbogen, A., Safirstein, B.E., Truong, D.D., Komjathy, S.F., Kegler-Ebo, D.M., Zhao, P., and Oh, C. (2019). Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson\u2019s disease. Park. Relat Disord.","DOI":"10.1016\/j.parkreldis.2019.03.026"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","article-title":"Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled phase 3 trial","volume":"18","author":"LeWitt","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/WCO.0000000000000354","article-title":"Continuous dopaminergic stimulation therapy for Parkinson\u2019s disease\u2013recent advances","volume":"29","author":"Timpka","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/mds.26528","article-title":"Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson\u2019s disease patients","volume":"31","author":"Antonini","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Double-blind, double-dummy, randomized study of continuous intrajejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.2174\/1389557518666180423113051","article-title":"A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?","volume":"18","author":"Cacciari","year":"2018","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_185","unstructured":"(2019). Safinamide for Parkinson\u2019s disease. Aust. Prescr., 42, 78\u201379."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00702-018-1900-6","article-title":"Levodopa-induced dyskinesia: Clinical features, incidence, and risk factors","volume":"125","author":"Tran","year":"2018","journal-title":"J. Neural Transm."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/mds.26125","article-title":"Clinical spectrum of levodopa-induced complications","volume":"30","author":"Aquino","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14656566.2018.1543407","article-title":"Chemical management of levodopa-induced dyskinesia in Parkinson\u2019s disease patients","volume":"20","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40265-016-0566-3","article-title":"Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia","volume":"76","author":"Vijayakumar","year":"2016","journal-title":"Drugs"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"37","DOI":"10.14802\/jmd.18046","article-title":"Less Pulsatile Levodopa Therapy (6 Doses Daily) Is associated with a Reduced Incidence of Dyskinesia","volume":"12","author":"Lin","year":"2019","journal-title":"J. Mov. Disord."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","article-title":"Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: Filling the bench-to-bedside gap","volume":"9","author":"Calabresi","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Sawada, H., Oeda, T., Kuno, S., Nomoto, M., Yamamoto, K., Yamamoto, M., Hisanaga, K., Kawamura, T., and Amantadine Study Group (2010). Amantadine for dyskinesias in Parkinson\u2019s disease: A randomized controlled trial. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015298"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mds.1112","article-title":"Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study","volume":"16","author":"Pavese","year":"2001","journal-title":"Mov. Disord."},{"key":"ref_194","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson\u2019s disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/14737175.2019.1592677","article-title":"Extended-Release Amantadine for Levodopa-Induced Dyskinesia","volume":"19","author":"Dashtipour","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","article-title":"ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial","volume":"74","author":"Pahwa","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/mds.26585","article-title":"Mavoglurant in Parkinson\u2019s patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies","volume":"31","author":"Trenkwalder","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2217\/nmt-2016-0005","article-title":"Nondopaminergic treatments for Parkinson\u2019s disease: Current and future prospects","volume":"6","author":"Freitas","year":"2016","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/mds.23687","article-title":"A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson\u2019s disease","volume":"26","author":"Wong","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/mds.23355","article-title":"Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson\u2019s disease","volume":"26","author":"Stathis","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.25418","article-title":"Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson\u2019s disease","volume":"28","author":"Mizuno","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","article-title":"Targeting adenosine A2A receptors in Parkinson\u2019s disease","volume":"29","author":"Schwarzschild","year":"2006","journal-title":"Trends Neurosci."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2009.06.008","article-title":"Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial","volume":"16","author":"Fernandez","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/brain\/awu409","article-title":"Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson\u2019s disease: A dose-finding study","volume":"138","author":"Svenningsson","year":"2015","journal-title":"Brain"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1212\/01.WNL.0000157058.17871.7B","article-title":"Acute akinesia in Parkinson disease","volume":"64","author":"Onofrj","year":"2005","journal-title":"Neurology"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/mds.20689","article-title":"Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, Parkinsonism-hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal","volume":"20","author":"Thomas","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"e649","DOI":"10.1097\/MD.0000000000000649","article-title":"Dopamine transporter single- photon emission computerized tomography supports diagnosis of akinetic crisis of parkinsonism and of neuroleptic malignant syndrome","volume":"94","author":"Martino","year":"2015","journal-title":"Medicine"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mds.23468","article-title":"Akinetic-rigid and tremor-dominant Parkinson\u2019s disease patients show different patterns of FP-CIT single photon emission computed tomography","volume":"26","author":"Eggers","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_209","first-page":"399","article-title":"Twenty-five years of amantadine therapy in Parkinson\u2019s Disease","volume":"46","author":"Danielczyk","year":"1995","journal-title":"J. Neural Transm. Suppl."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.62.6_suppl_4.S1","article-title":"Rapid treatment of \u201coff\u201d episodes. Will this change Parkinson disease therapy?","volume":"62","author":"Stacy","year":"2004","journal-title":"Neurology"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jocn.2008.02.015","article-title":"Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis","volume":"16","author":"Dafotakis","year":"2009","journal-title":"J. Clin. Neurosci."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"e1118","DOI":"10.1097\/MD.0000000000001118","article-title":"Critical Illness Neuromyopathy Complicating Akinetic Crisis in Parkinsonism: Report of 3 Cases","volume":"94","author":"Capasso","year":"2015","journal-title":"Medicine"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41582-019-0155-7","article-title":"Emerging therapies in Parkinson disease\u2014Repurposed drugs and new approaches","volume":"15","author":"Elkouzi","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/ene.12889","article-title":"A consensus review on the development of palliative care for patients with chronic and progressive neurological disease","volume":"23","author":"Oliver","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1016\/S1353-8020(09)70819-3","article-title":"Multidisciplinary care for patients with Parkinson\u2019s disease","volume":"15","author":"Kalf","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14737175.2019.1561285","article-title":"Multidisciplinary care for people with Parkinson\u2019s disease: The new kids on the block!","volume":"19","author":"Radder","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S1353-8020(13)70030-0","article-title":"Exercise: Is it a neuroprotective and if so, how does it work?","volume":"20","author":"Zigmond","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1212\/WNL.0000000000000644","article-title":"Phase I\/II randomized trial of aerobic exercise in Parkinson disease in a community setting","volume":"83","author":"Uc","year":"2014","journal-title":"Neurology"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1097\/MD.0000000000000411","article-title":"A systematic review and meta-analysis of strength training in individuals with multiple sclerosis or Parkinson disease","volume":"94","author":"Cruickshank","year":"2015","journal-title":"Medicine"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jamaneurol.2013.646","article-title":"Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease","volume":"70","author":"Shulman","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Deane, K.H., Whurr, R., Playford, E.D., Ben-Shlomo, Y., and Clarke, C.E. (2001). Speech and language therapy for dysarthria in Parkinson\u2019s disease. Cochrane Database Syst. Rev., CD002812.","DOI":"10.1002\/14651858.CD002816"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MOO.0000000000000151","article-title":"Evidence-based treatment of voice and speech disorders in Parkinson disease","volume":"23","author":"Mahler","year":"2015","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/WCO.0b013e3283632d08","article-title":"Deep brain stimulation for Parkinson\u2019s disease and other movement disorders","volume":"26","author":"Kalia","year":"2013","journal-title":"Curr. Opin. Neurol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa060281","article-title":"A randomized trial of deep-brain stimulation for Parkinson\u2019s disease","volume":"355","author":"Deuschl","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","article-title":"Pallidal versus subthalamic deep-brain stimulation for Parkinson\u2019s disease","volume":"362","author":"Follett","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1205158","article-title":"Neurostimulation for Parkinson\u2019s disease with early motor complications","volume":"368","author":"Schuepbach","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"11986","DOI":"10.1523\/JNEUROSCI.1568-13.2013","article-title":"Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: A tale of two systems","volume":"33","author":"Grabli","year":"2013","journal-title":"J. Neurosci."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1097\/00001756-200412030-00012","article-title":"Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey","volume":"15","author":"Jenkinson","year":"2004","journal-title":"Neuroreport"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/brain\/awt122","article-title":"Nigral stimulation for resistant axial motor impairment in Parkinson\u2019s disease? A randomized controlled trial","volume":"136","author":"Weiss","year":"2013","journal-title":"Brain"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.parkreldis.2018.03.009","article-title":"Freezing of gait: Promising avenues for future treatment","volume":"52","author":"Gilat","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_232","first-page":"521","article-title":"Efficacy of cumulative high-frequency rTMS on freezing of gait in Parkinson\u2019s disease","volume":"33","author":"Kim","year":"2015","journal-title":"Restor. Neurol. Neurosci."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.neubiorev.2015.08.010","article-title":"Transcranial direct current stimulation in Parkinson\u2019s disease: Neurophysiological mechanisms and behavioral effects","volume":"57","author":"Broeder","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.25897","article-title":"Transcranial direct current stimulation for treatment of freezing of gait: A cross-over study","volume":"29","author":"Valentino","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.27300","article-title":"Multitarget transcranial direct current stimulation for freezing of gait in Parkinson\u2019s disease","volume":"33","author":"Dagan","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1176\/appi.ajp.2011.10111669","article-title":"Cognitive-behavioral therapy for depression in Parkinson\u2019s disease: A randomized, controlled trial","volume":"168","author":"Dobkin","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/1756285613495723","article-title":"Anxiety in Parkinson\u2019s disease: Identification and management","volume":"7","author":"Chen","year":"2014","journal-title":"Adv. Neurol. Disord."},{"key":"ref_238","first-page":"8104673","article-title":"Cognitive Stimulation for Individuals with Parkinson\u2019s Disease Dementia Living in Long-Term Care: Preliminary Data from a Randomized Crossover Pilot Study","volume":"2018","author":"Folkerts","year":"2018","journal-title":"Park. Dis."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1007\/s00415-019-09329-6","article-title":"Parkinson\u2019s-adapted cognitive stimulation therapy: Feasibility and acceptability in Lewy body spectrum disorders","volume":"266","author":"McCormick","year":"2019","journal-title":"J. Neurol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","article-title":"Summary of the recommendations of the EFNS\/MDS-ES reviewon therapeutic management of Parkinson\u2019s disease","volume":"20","author":"Ferreira","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(12)70049-2","article-title":"Treatment of motor and non-motor features of Parkinson\u2019s disease with deep brain stimulation","volume":"11","author":"Fasano","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.brs.2015.07.043","article-title":"Double-blind Randomized Trial of tDCS Versus Sham in Parkinson Patients with Mild Cognitive Impairment Receiving Cognitive Training","volume":"8","author":"Biundo","year":"2015","journal-title":"Brain Stimul."},{"key":"ref_243","first-page":"CD010916","article-title":"Transcranial direct current stimulation (tDCS) for idiopathic Parkinson\u2019s disease","volume":"7","author":"Elsner","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s40265-015-0497-4","article-title":"Disease-Modifying Drugs in Parkinson\u2019s Disease","volume":"75","author":"Park","year":"2015","journal-title":"Drugs"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.27360","article-title":"Disease Modification in Parkinson\u2019s Disease: Current Approaches, Challenges, and Future Considerations","volume":"33","author":"Lang","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit","volume":"71","author":"Beal","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz, K., Tilley, B.C., Elm, J.J., Babcock, D., Hauser, R., Ross, G.W., Augustine, A.H., Augustine, E.U., and Aminoff, M.J. (2015). Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: A randomized clinical trial. JAMA, 313, 584\u2013593.","DOI":"10.1001\/jama.2015.120"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/srep04874","article-title":"The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson\u2019s disease","volume":"4","author":"Karuppagounder","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lyso- somal biochemistry in glucocerebrosidase mutation-linked Parkin-son disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 Antisense Oligonucleotides Ameliorate \u03b1-Synuclein Inclusion Formation in a Parkinson\u2019s Disease Mouse Model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnera-bility in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_253","unstructured":"Simuni, T. (2019, January 4\u201310). A phase 3 study of isradipine as a disease-modifying agent in patients with early Parkinson\u2019s disease (STEADY-PD III): Final study results. Proceedings of the 2019 American Academy of Neurology Annual Meeting, Philadelphia, PA, USA."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ana.410360612","article-title":"Complex I, iron, and ferritin in Parkinson\u2019s disease substantia nigra","volume":"36","author":"Mann","year":"1994","journal-title":"Ann. Neurol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) recep-tor as a therapeutic target in Parkinson\u2019s disease: Mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1212\/WNL.0000000000004568","article-title":"Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD): A randomized trial","volume":"89","author":"Postuma","year":"2017","journal-title":"Neurology"},{"key":"ref_258","first-page":"545","article-title":"Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson\u2019s Disease: Rationale for Clinical Trial, and Current Progress","volume":"7","author":"Carroll","year":"2017","journal-title":"J. Park. Dis."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/j.1471-4159.2006.04078.x","article-title":"Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates","volume":"98","author":"Quik","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrneurol.2017.128","article-title":"Long-term effects of exercise and physical therapy in people with Parkinson disease","volume":"13","author":"Mak","year":"2017","journal-title":"Nat. Rev. Neurol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/9\/8\/388\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:12:33Z","timestamp":1760188353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/9\/8\/388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,20]]},"references-count":260,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["biom9080388"],"URL":"https:\/\/doi.org\/10.3390\/biom9080388","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,20]]}}}